1. Home
  2. PRTA
  3. PRTA News

Latest Prothena Corporation plc (PRTA) News on September 19, 2025

Prothena to lay off majority of staff; Zealand shares obesity drug data
PRTA

BioPharma Dive

3 months ago

Prothena to lay off majority of staff; Zealand shares obesity drug data

Prothena Announces Corporate Restructuring
PRTA

Business Wire

3 months ago

Prothena Announces Corporate Restructuring

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
PRTA

Insider Monkey

3 months ago

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
PRTA

TipRanks

3 months ago

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
PRTA

BioPharma Dive

3 months ago

Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
PRTA

Zacks

3 months ago

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

PRTA

MT Newswires

3 months ago

Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
PRTA

Business Wire

3 months ago

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails
PRTA

Insider Monkey

4 months ago

Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
PRTA

Insider Monkey

4 months ago

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform

PRTA

MT Newswires

4 months ago

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target

PRTA

MT Newswires

4 months ago

Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results
PRTA

Insider Monkey

4 months ago

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
PRTA

Zacks

4 months ago

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

PRTA

MT Newswires

4 months ago

Top Premarket Decliners

Biogen strikes RNAi deal with City; Aurion withdraws IPO
PRTA

BioPharma Dive

4 months ago

Biogen strikes RNAi deal with City; Aurion withdraws IPO

Why Is Prothena Stock Trading Lower On Tuesday?
PRTA

Benzinga

4 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

PRTA

MT Newswires

4 months ago

Oppenheimer Downgrades Prothena to Market Perform From Outperform

PRTA

MT Newswires

4 months ago

Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32

PRTA

MT Newswires

4 months ago

Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating

Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint
PRTA

Clinical Trials Arena

4 months ago

Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint

PRTA

MT Newswires

4 months ago

Prothena to Stop Birtamimab Development After Trial for AL Amyloidosis Fails to Meet Primary Endpoint

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
PRTA

Business Wire

4 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
PRTA

Zacks

4 months ago

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

PRTA

MT Newswires

4 months ago

RBC Trims Price Target on Prothena to $18 From $20, Keeps Sector Perform, Speculative Risk

Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?
PRTA

Insider Monkey

4 months ago

Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
PRTA

Zacks

4 months ago

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

PRTA

Associated Press Finance

4 months ago

Prothena: Q1 Earnings Snapshot

Prothena Reports First Quarter 2025 Financial Results and Business Highlights
PRTA

Business Wire

4 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Insiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458m
PRTA

Simply Wall St.

4 months ago

Insiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458m

PRTA

MT Newswires

5 months ago

Prothena Corp Public Ltd Insider Bought Shares Worth $2,749,916, According to a Recent SEC Filing

Prothena to Report First Quarter 2025 Financial Results on May 8
PRTA

Business Wire

5 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Full Year 2024 Earnings: Misses Expectations
PRTA

Simply Wall St.

7 months ago

Prothena Full Year 2024 Earnings: Misses Expectations

Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
PRTA

Zacks

7 months ago

Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus

PRTA

MT Newswires

7 months ago

RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk

Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
PRTA

GuruFocus.com

7 months ago

Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...

Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
PRTA

Zacks

7 months ago

Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates

PRTA

Associated Press Finance

7 months ago

Prothena: Q4 Earnings Snapshot

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
PRTA

Business Wire

7 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
PRTA

Business Wire

7 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Further weakness as Prothena (NASDAQ:PRTA) drops 16% this week, taking three-year losses to 61%
PRTA

Simply Wall St.

7 months ago

Further weakness as Prothena (NASDAQ:PRTA) drops 16% this week, taking three-year losses to 61%

BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
PRTA

Zacks

8 months ago

BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug

Prothena Announces Board of Directors Update
PRTA

Business Wire

9 months ago

Prothena Announces Board of Directors Update

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
PRTA

Simply Wall St.

9 months ago

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

PRTA

MT Newswires

9 months ago

Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
PRTA

Investor's Business Daily

9 months ago

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease

Prothena’s Parkinson’s study fails primary endpoint despite some success
PRTA

Clinical Trials Arena

9 months ago

Prothena’s Parkinson’s study fails primary endpoint despite some success

PRTA

MT Newswires

9 months ago

Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
PRTA

Business Wire

9 months ago

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
PRTA

Zacks

9 months ago

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
PRTA

Zacks

10 months ago

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA

Zacks

10 months ago

Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
PRTA

Zacks

10 months ago

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

PRTA

Associated Press Finance

10 months ago

Prothena: Q3 Earnings Snapshot

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
PRTA

Business Wire

10 months ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
PRTA

Zacks

10 months ago

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Prothena to Report Third Quarter 2024 Financial Results on November 12
PRTA

Business Wire

10 months ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
PRTA

Zacks

a year ago

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
PRTA

Zacks

a year ago

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?

State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings
PRTA

GuruFocus.com

a year ago

State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings

PRTA

MT Newswires

a year ago

Update: Prothena's Shares Fall as Chief Medical Officer Departs

PRTA

MT Newswires

a year ago

Prothena Names Chad Swanson as Chief Development Officer; Chief Medical Officer Departs

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
PRTA

Zacks

a year ago

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

Prothena to Participate in Upcoming Healthcare Conferences
PRTA

Business Wire

a year ago

Prothena to Participate in Upcoming Healthcare Conferences

What Makes Prothena (PRTA) a New Buy Stock
PRTA

Zacks

a year ago

What Makes Prothena (PRTA) a New Buy Stock

Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
PRTA

Insider Monkey

a year ago

Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks

PRTA

MT Newswires

a year ago

Oppenheimer Cuts Prothena Price Target to $62 From $66, Outperform Rating Maintained

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
PRTA

Zacks

a year ago

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
PRTA

Zacks

a year ago

Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates

PRTA

Associated Press Finance

a year ago

Prothena: Q2 Earnings Snapshot

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
PRTA

Business Wire

a year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8
PRTA

Business Wire

a year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PRTA

Zacks

a year ago

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PRTA

Zacks

a year ago

Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
PRTA

Zacks

a year ago

Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
PRTA

Zacks

a year ago

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
PRTA

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
PRTA

Zacks

a year ago

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
PRTA

Zacks

a year ago

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
PRTA

Investor's Business Daily

a year ago

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
PRTA

Zacks

a year ago

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
PRTA

Zacks

a year ago

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
PRTA

Zacks

a year ago

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
PRTA

Zacks

a year ago

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
PRTA

Zacks

a year ago

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

BMS stakes $80m on Prothena’s neurodegenerative candidate
PRTA

Pharmaceutical Technology

a year ago

BMS stakes $80m on Prothena’s neurodegenerative candidate

PRTA

MT Newswires

a year ago

Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
PRTA

Business Wire

a year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
PRTA

Simply Wall St.

a year ago

News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts

Analysts Have Lowered Expectations For Prothena Corporation plc (NASDAQ:PRTA) After Its Latest Results
PRTA

Simply Wall St.

a year ago

Analysts Have Lowered Expectations For Prothena Corporation plc (NASDAQ:PRTA) After Its Latest Results

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
PRTA

Zacks

a year ago

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
PRTA

Zacks

a year ago

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

PRTA

Associated Press Finance

a year ago

Prothena: Q1 Earnings Snapshot

Prothena Reports First Quarter 2024 Financial Results and Business Highlights
PRTA

Business Wire

a year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

We think Prothena Corporation plc's (NASDAQ:PRTA) CEO May Struggle To See Much Of A Pay Rise This Year
PRTA

Simply Wall St.

a year ago

We think Prothena Corporation plc's (NASDAQ:PRTA) CEO May Struggle To See Much Of A Pay Rise This Year

Prothena to Report First Quarter 2024 Financial Results on May 8
PRTA

Business Wire

a year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
PRTA

Zacks

a year ago

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
PRTA

Business Wire

a year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
PRTA

Investor's Business Daily

a year ago

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
PRTA

Zacks

a year ago

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

Share on Social Networks: